ID
45804
Beschrijving
Principal Investigator: Jean J. Zhao, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA MeSH: Breast Neoplasms,Neoplasm Metastasis,Brain Neoplasms,Neoplasm Transplantation,Molecular Targeted Therapy https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001063 We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived xenograft (PDX) models tested. We performed whole exome sequencing analysis of these PDX tumors and their matched blood and patient samples to investigate drug sensitive and resistance mechanisms. Our sequencing data revealed an interesting association of genotyping and phenotyping with tumors responses to drug treatment.
Link
Trefwoorden
Versies (1)
- 23-06-23 23-06-23 - Chiara Middel
Houder van rechten
Jean J. Zhao, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Geüploaded op
23 juni 2023
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs001063 Genomic Characterization of PDX Models for Breast Cancer Brain Metastases
This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This subject phenotype table contains subject ID, gender, and age at surgery.
- This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
Similar models
This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This subject phenotype table contains subject ID, gender, and age at surgery.
- This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
C1299222 (UMLS CUI [1,2])
C0456205 (UMLS CUI [1,2])
C0936012 (UMLS CUI [1,3])
C4050317 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C1512413 (UMLS CUI [1,2])
C0034804 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,3])
C2919590 (UMLS CUI [1,2])
C2985566 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C0392920 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C0279025 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C1522449 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])